Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study

  • Ryo Ando1
  • Aki Kato2
  • Kenichi Kimoto3
  • Maho Itotani4
  • Taiichi Hikichi5
  • Goro Watanabe6
  • Taku Sato7
  • Hideho Matsuda8
  • Satomi Shiose9
  • Hisashi Matsubara10
  • Susumu Ishida1
10 affiliations
  1. 1Department of Ophthalmology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
  2. 2Department of Ophthalmology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
  3. 3Department of Ophthalmology, Nishida Hospital, Saiki 876-0047, Japan
  4. 4Department of Ophthalmology, Oita University Faculty of Medicine, Yufu 879-5593, Japan
  5. 5Hikichi Eye Clinic, Sapporo 060-0807, Japan
  6. 6Department of Ophthalmology, Yayoi Hospital, Toyohashi 441-8106, Japan
  7. 7Takasaki Sato Eye Clinic, Takasaki 370-0036, Japan
  8. 8Matsuda Eye Clinic, Shiojiri 399-0738, Japan
  9. 9Department of Ophthalmology, Kyushu University Hospital, Fukuoka 812-8582, Japan
  10. 10Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan
Open at sourceDOICite

Abstract

Background/Objectives: Brolucizumab is a potent therapeutic option for neovascular age-related macular degeneration (nAMD), but carries risks of intraocular inflammation (IOI), retinal vasculitis (RV), and retinal vascular occlusion (RO). This study evaluated the occurrence of these adverse events in eyes treated with intravitreal brolucizumab injection (IVBr) under a treatment strategy incorporating sub-Tenon injection of triamcinolone acetonide (STTA). Methods: This multicenter retrospective study included patients with nAMD who initiated IVBr treatment with STTA and were followed for at least 1 month. IVBr was administered under a treatment strategy incorporating STTA, with repeat STTA when more than 3 months had elapsed since the previous STTA. Results: The study included 80 eyes of 80 patients (59 men and 21 women; mean age, 74.5 ± 7.7 years) from 9 institutions. The mean number of previous intravitreal anti-vascular endothelial growth factor injections was 20.4 ± 18.3. The mean follow-up period was 6.8 ± 4.8 months. The mean numbers of IVBr and STTA administrations were 2.6 ± 1.6 and 1.7 ± 1.0 per eye, respectively. Three eyes (3.75%) developed adverse events: one developed IOI, one developed IOI with RV, and one developed RO without IOI or RV. Conclusions: IOI, RV, and RO occurred in 2.5%, 1.25%, and 1.25% of eyes, respectively. These data may help inform the design and sample-size planning of future prospective comparative studies.

Related

  1. Association between postoperative serum calcium and complications after pancreaticoduodenectomy in a retrospective multicenter study
    Tiantian Huang, Sicheng Pu, Wenyuan Xie +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  2. Clinical Characteristics of Patients Presenting with Moderate-to-Severe Atopic Dermatitis and Concomitant Inflammatory Bowel Diseases: a Multicenter Retrospective Study.
    Elena Pezzolo, Maddalena Napolitano, Martina Maurelli +12
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Machine Learning–Based Prediction of Major Postoperative Complications After Noncardiac Surgery Under General Anesthesia Using Routinely Available Electronic Health Record Data: Retrospective Multicenter Development and Validation Study
    Takuya Nishino, Hiroshi Mase, Chol Kim +3
    JMIR Perioperative MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicinePMC
  4. Postcardiotomy extracorporeal life support after isolated or valve-concomitant coronary artery bypass grafting: An observational multicenter study
    Silvia Mariani, Sacha Matteucci, Bas van Bussel +36
    Journal of Thoracic and Cardiovascular Surgery openPeer-reviewedCC BYGeneral biologyEpidemiology & public healthHAL
  5. Outcomes of Surgical Versus Transcatheter Mitral Valve Repair or Replacement in Patients With Myocardial Infarction and Concomitant Mitral Regurgitation: A Retrospective Analysis of Real-World Data
    Judah Rajendran, Akiva Rosenzveig, Nishitha Vempalli +6
    Journal of the Society for Cardiovascular Angiography & InterventionsPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMCEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ando2026brolucizumabassociated,
  title = {{Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study}},
  author = {Ryo Ando and Aki Kato and Kenichi Kimoto and Maho Itotani and Taiichi Hikichi and Goro Watanabe and Taku Sato and Hideho Matsuda and Satomi Shiose and Hisashi Matsubara and Susumu Ishida},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = nov,
  doi = {10.3390/jcm15218507},
  url = {https://www.mdpi.com/2077-0383/15/21/8507},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study
AU  - Ryo Ando
AU  - Aki Kato
AU  - Kenichi Kimoto
AU  - Maho Itotani
AU  - Taiichi Hikichi
AU  - Goro Watanabe
AU  - Taku Sato
AU  - Hideho Matsuda
AU  - Satomi Shiose
AU  - Hisashi Matsubara
AU  - Susumu Ishida
PY  - 2026
DA  - 2026/11/02
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218507
UR  - https://www.mdpi.com/2077-0383/15/21/8507
AB  - Background/Objectives: Brolucizumab is a potent therapeutic option for neovascular age-related macular degeneration (nAMD), but carries risks of intraocular inflammation (IOI), retinal vasculitis (RV), and retinal vascular occlusion (RO). This study evaluated the occurrence of these adverse events in eyes treated with intravitreal brolucizumab injection (IVBr) under a treatment strategy incorporating sub-Tenon injection of triamcinolone acetonide (STTA). Methods: This multicenter retrospective study included patients with nAMD who initiated IVBr treatment with STTA and were followed for at least 1 month. IVBr was administered under a treatment strategy incorporating STTA, with repeat STTA when more than 3 months had elapsed since the previous STTA. Results: The study included 80 eyes of 80 patients (59 men and 21 women; mean age, 74.5 ± 7.7 years) from 9 institutions. The mean number of previous intravitreal anti-vascular endothelial growth factor injections was 20.4 ± 18.3. The mean follow-up period was 6.8 ± 4.8 months. The mean numbers of IVBr and STTA administrations were 2.6 ± 1.6 and 1.7 ± 1.0 per eye, respectively. Three eyes (3.75%) developed adverse events: one developed IOI, one developed IOI with RV, and one developed RO without IOI or RV. Conclusions: IOI, RV, and RO occurred in 2.5%, 1.25%, and 1.25% of eyes, respectively. These data may help inform the design and sample-size planning of future prospective comparative studies.
SN  - 2077-0383
ER  -